Oxaliplatin Injection, Solution
Product Images NDC 72603-420

8 FDA label images from Northstar Rx Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 72603-420). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Oxali Ns Structure)

Structure (Oxali Ns Structure)
Chemical structure of oxaliplatin showing a platinum atom coordinated with amine and oxalate ligands. The image illustrates the molecular arrangement typical of oxaliplatin, an intravenous injection solution drug.*
FDA Label Image

Figure 1 (Oxali Ns Fig 1)

Figure 1 (Oxali Ns Fig 1)
A Kaplan-Meier survival curve comparing disease-free survival probability over months between two treatment arms labeled FOLFOX4 and LV5FU2. The graph shows the number of patients at risk at various time points up to 72 months, hazard ratio with confidence interval, and a p-value from a stratified logrank test, indicating statistical comparison of the two groups.*
FDA Label Image

Figure 2 (Oxali Ns Fig 2)

Figure 2 (Oxali Ns Fig 2)
A Kaplan-Meier survival curve chart showing disease-free survival (DFS) probability over time in months for Stage III patients. The chart compares two treatment arms: FOLFOX4 versus LV5FU2, both combined with DUKES C, with DFS probability on the y-axis and time in months on the x-axis. Statistical values including a hazard ratio with 95% confidence interval and a p-value from the logrank test are displayed.*
FDA Label Image

Figure 3 (Oxali Ns Fig 3)

Figure 3 (Oxali Ns Fig 3)
A survival curve chart comparing the percentage of patients surviving over 24 months among three treatment groups: Oxaliplatin + 5-FU/LV, Oxaliplatin + irinotecan, and Irinotecan + 5-FU/LV. The chart shows median survival times in months for each group, with Oxaliplatin + 5-FU/LV having the highest median survival of 19.4 months. The chart includes a p-value indicating statistical significance.*
FDA Label Image

Principal Display Panel – Oxaliplatin Injection, Usp 50 mg Vial Label (Oxali 50mg Ns Vial V2)

Principal Display Panel – Oxaliplatin Injection, Usp 50 mg Vial Label (Oxali 50mg Ns Vial V2)
Label for Oxaliplatin Injection, USP, 50 mg per 10 mL (5 mg per mL) intravenous injection solution in a 10 mL single-dose vial by Northstar Rx LLC. The label includes warnings about not diluting in sodium chloride-containing solutions, storage instructions, and dosage information.*
FDA Label Image

Principal Display Panel – Oxaliplatin Injection, Usp 50 mg Carton (Oxali 50mg Ns Carton V3)

Principal Display Panel – Oxaliplatin Injection, Usp 50 mg Carton (Oxali 50mg Ns Carton V3)
Oxaliplatin 50 mg per 10 mL (5 mg per mL) injection, USP, intravenous solution in a single-dose vial. The label highlights that it is a sterile aqueous, preservative-free solution that must be diluted prior to use with 5% dextrose injection and cautions against dilution in sodium chloride or chloride-containing solutions. The package is labeled for Northstar Rx LLC and includes storage and handling instructions.*
FDA Label Image

Principal Display Panel – Oxaliplatin Injection, Usp 100 mg Vial Label (Oxali 100mg Ns Vial V2)

Principal Display Panel – Oxaliplatin Injection, Usp 100 mg Vial Label (Oxali 100mg Ns Vial V2)
Oxaliplatin Injection, USP, 100 mg per 20 mL (5 mg per mL) solution for intravenous use. The label indicates a 20 mL single-dose vial, cautions against dilution with sodium chloride-containing solutions, and notes the product is preservative-free. It is labeled for use by Northstar Rx LLC, Memphis, TN, with storage instructions and a barcode on the right side.*
FDA Label Image

Principal Display Panel – Oxaliplatin Injection, Usp 100 mg Carton (Oxali 100mg Ns Carton V3)

Principal Display Panel – Oxaliplatin Injection, Usp 100 mg Carton (Oxali 100mg Ns Carton V3)
Packaging label for Oxaliplatin Injection, USP 100 mg per 20 mL (5 mg per mL) solution for intravenous use. The label displays warnings including 'Cytotoxic Agent' and 'Do Not Dilute in Sodium Chloride/Chloride-Containing Solutions.' It indicates a sterile aqueous, preservative-free solution to be diluted prior to use with 5% Dextrose Injection. The label is marked for Rx only and shows the labeler as Northstar Rx LLC, with manufacturing details from Kindos Pharmaceuticals Co., Ltd., Chengdu, China.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.